Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 328Fallopian Tube Neoplasms 153Carcinoma, Ovarian Epithelial 115Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Neoplasms 28Breast Neoplasms 27Peritoneal Neoplasms 24Brenner Tumor 24Carcinoma, Non-Small-Cell Lung 21Stomach Neoplasms 18Recurrence 17Neoplasm Metastasis 14Uterine Neoplasms 13Testicular Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Melanoma 9Testicular Germ Cell Tumor 8Central Nervous System Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Esophageal Neoplasms 7Carcinoma 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neurotoxicity Syndromes 6Carcinosarcoma 6

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Metastatic Breast Cancer × Paclitaxel × Gynecologic × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡